Insider transactions

Maha Katabi

CIK 1720685 · last filed 2025-05-16

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$217.11M
Companies
5
Total Filings
24
Lifetime Open-Market Net
$6.40M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

VERA price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
SOFINNOVA INVESTMENTS
3000 SAND HILL ROAD, 4-250
MENLO PARK, CA 94025
Related Filers
Sofinnova Management X, L.P. — 11 joint filings, latest 2023-02-27
Sofinnova Venture Partners X, L.P. — 11 joint filings, latest 2023-02-27
James Healy — 6 joint filings, latest 2023-02-27
Michael Powell — 5 joint filings, latest 2021-02-09
Inozyme Pharma, Inc. — 2 joint filings, latest 2020-07-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
VERA Director 7,062,846 $30.74 $217.11M -$15.10M 10 2025-05-16
Jade Biosciences, Inc. (AVTE) Delisted Director 97,187 $93.80 $9.12M $5.00M 8 2024-06-07
RayzeBio, Inc. (RYZB) Delisted Director 0 $62.49 $0 $8.50M 3 2024-02-27
Inozyme Pharma, Inc. (INZY) Delisted 10%+ Owner 2,028,308 $4.00 $8.11M $7.00M 1 2020-07-28
Akouos, Inc. (AKUS) Delisted 10%+ Owner 1,515,073 $13.29 $20.14M $1000.0K 1 2020-07-01

Recent Filings · Page 2 of 3

24 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-06-08 Jade Biosciences, Inc. (AVTE) Delisted Grant (A) — $0 EDGAR
2023-05-12 VERA Grant (A) — $0 EDGAR
2023-02-08 VERA Buy (P) +285,714 $2.00M EDGAR
2023-01-05 Jade Biosciences, Inc. (AVTE) Delisted Grant (A) — $0 EDGAR
2022-06-22 Jade Biosciences, Inc. (AVTE) Delisted Grant (A) — $0 EDGAR
2022-05-26 VERA Grant (A) — $0 EDGAR
2022-02-14 VERA Buy (P) +266,666 $4.00M EDGAR
2022-01-05 Jade Biosciences, Inc. (AVTE) Delisted Grant (A) — $0 EDGAR
2021-07-06 Jade Biosciences, Inc. (AVTE) Delisted Mixed +3,758,686 $5.00M EDGAR
2021-07-01 Jade Biosciences, Inc. (AVTE) Delisted Grant (A) — $0 EDGAR
Showing 11–20 of 24
Page 2 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.